DoD Breast Cancer Era of Hope Scholar Award | HT942525BCRPEOHS

Frequently Asked Questions (FAQs)

1) What is the DoD Breast Cancer Era of Hope Scholar Award (FY25)?

The DoD Breast Cancer Era of Hope Scholar Award (FY25) is a discretionary federal grant under the Department of Defense (DoD) Breast Cancer Research Program (BCRP), administered by the U.S. Army Medical Research Acquisition Activity (USAMRAA). It is designed to support early-career investigators who have already demonstrated unusual promise and who are positioned to make a meaningful, long-term impact on breast cancer research.

2) What is the main purpose of this award?

The award aims to identify and accelerate the careers of exceptionally creative, high-impact early-career scientists who can introduce innovative directions that could help end breast cancer. The program is looking for investigators likely to become influential leaders in the field.

3) Is this award focused on a specific research project or the investigator?

The emphasis is intentionally placed on the investigator rather than on a single narrowly defined project. The program prioritizes the person: their track record of high-impact thinking, creativity, and potential for leadership, rather than only the strength of a specific project plan.

4) Who administers this funding opportunity?

The opportunity is administered by the U.S. Army Medical Research Acquisition Activity (USAMRAA) under the DoD Breast Cancer Research Program (BCRP).

5) What kinds of investigators is the program trying to support?

The program is targeting early-career investigators who have already shown unusual promise. It is aimed at researchers who consistently go beyond conventional approaches, demonstrate scientific excellence, and show strong potential to shape and lead the future of breast cancer research.

6) What does the program mean by seeking the "best and brightest"?

Based on the description provided, "best and brightest" refers to scientists with a demonstrated pattern of creative, high-impact thinking, and the ability to propose fresh, innovative directions. The award is highly selective and intended for individuals with clear potential to become leaders who can shift the trajectory of breast cancer research.

7) Are collaborations and partnerships important for this award?

Yes. Applicants are expected to show an ability to build effective partnerships and collaborations. The program is interested in investigators who can connect disciplines, bring teams together, and accelerate progress through cooperative work.

8) Do applications need to align with specific program priorities or challenges?

Yes. Applications are expected to align with the FY25 BCRP overarching challenges. The only exception mentioned is if the applicant provides a strong and convincing justification for why an exception is warranted.

9) What time commitment is required from the Principal Investigator (PI)?

The PI must dedicate at least 25 percent level of time and effort throughout the award period to conducting breast cancer research supported by this funding. This requirement signals that the scholar is expected to be deeply involved in the supported research rather than serving only in an oversight role.

10) Are breast cancer consumer advocates required as part of the research team?

Yes. The research team must include two or more breast cancer consumer advocates. This reflects the DoD BCRP tradition of incorporating the patient and survivor perspective directly into the research process to improve relevance, accountability, and real-world impact.

11) How many consumer advocates are required?

At least two breast cancer consumer advocates must be included on the research team.

12) Why does the program require consumer advocates?

The requirement reinforces the BCRP approach of integrating the patient and survivor perspective directly into research. The stated purpose is to improve the relevance of the work, strengthen accountability, and increase real-world impact.

13) What is the Funding Opportunity Number for this announcement?

The Funding Opportunity Number is HT942525BCRPEOHS.

14) What activity category does this opportunity fall under?

This opportunity falls under the Science and Technology/Research and Development activity category.

15) What is the CFDA number associated with this opportunity?

The listing is associated with CFDA number 12.420.

16) Who is eligible to apply?

Eligibility is listed as unrestricted, which suggests a broad applicant pool. No additional eligibility limits are provided in the information given.

17) What is the application deadline?

The original application closing date is June 27, 2025.

18) How many awards does the agency expect to make?

The agency anticipates making about two awards.

19) What is the maximum funding amount (award ceiling)?

The award ceiling is not specified in the provided listing.

20) How competitive is this award likely to be?

Based on the description, it is highly selective. The program intends to elevate exceptional early-career leaders, and the agency anticipates making about two awards, which suggests a very competitive opportunity.

21) What makes this award different from a typical research grant?

The defining feature described is the focus on the investigator rather than a narrowly defined project. The award is framed as a career-accelerating mechanism for researchers with demonstrated creativity, leadership potential, and collaborative strength, while still expecting alignment with BCRP challenges (or a strong justification for an exception).

22) What expectations are set about the PI's engagement in the research?

The PI is expected to be substantially engaged in the breast cancer research supported by the award, as reflected by the requirement to devote at least 25 percent time and effort across the award period.

23) Does the opportunity require a team-based approach?

The information provided emphasizes collaboration and explicitly requires inclusion of two or more consumer advocates on the research team, which signals a team-based and stakeholder-engaged approach.

24) What is the overall way to understand the Era of Hope Scholar Award?

It is best understood as a highly selective, career-accelerating award intended to elevate exceptional early-career researchers whose creativity, collaborative capabilities, and commitment are expected to materially advance and potentially transform breast cancer research.